ATM germline pathogenic confers ~5-10× pancreatic-cancer risk; PARPi activity in ATM-muta...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ATM-GERMLINE-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | ATM germline pathogenic |
| Disease | DIS-PDAC |
| ESCAT tier | IIA |
| Recommended combinations | FOLFIRINOX or gem-cis (platinum induction), olaparib maintenance (off-label, NCCN-listed for HRR-mut) |
| Evidence summary | ATM germline pathogenic confers ~5-10× pancreatic-cancer risk; PARPi activity in ATM-mutated PDAC is modest (POLO germline-only, BRCA-restricted). NCCN recommends platinum-based chemo first; PARPi off-label or trial-only. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing mandatory. ATM PDAC carriers eligible for high-risk surveillance protocols (CAPS).
Used By
No reverse references found in the YAML corpus.